Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pneumonia was produced in nine, conventionally reared calves by intrabronchial inoculation with Haemophilus somnus. Volumes of pneumonic lung were determined stereologically, following serial slicing of lungs fixed by vascular perfusion. Twenty-four hours after inoculation, consistent findings were: neutrophilic to fibrinoid vasculitis, degeneration of alveolar macrophages, necrotizing bronchiolitis, suppurative bronchopneumonia, lobular necrosis, and dilation and thrombosis of lymphatics. Bacteria were identified histologically by an immunoperoxidase technic and were either free in alveoli or associated with degenerative alveolar macrophages. The latter suggests that macrophage degeneration may be a result of bacteria/macrophage interaction. Immune complex deposition is unlikely to be the principal mechanism for the vasculitis because bacterial antigen was not generally found in necrotic vessel walls, and two colostrum-deprived, H. somnus antibody-negative calves also had neutrophilic vasculitis 12 to 24 hours after inoculation with the lowest dose of H. somnus used in the above experiment.
 ...
PMID:Experimental Haemophilus somnus pneumonia in calves and immunoperoxidase localization of bacteria. 330 6

Flomoxef (FMOX, 6315-S), a new antibacterial drug, was administered to 9 cases with respiratory tract infections for a duration of 8 approximately 16 days at a daily dose of 2 g. Diagnosis of these patients were bronchopneumonia 5 cases, chronic bronchitis 3 cases and acute bronchitis 1 case. From transtracheal aspiration several organisms were isolated; Haemophilus influenzae was isolated in 3 cases, Streptococcus pneumoniae in 3 cases, H. influenzae plus Branhamella catarrhalis in 1 case, Streptococcus dysgalactiae plus Neisseria meningitidis in 1 case and Corynebacterium pseudodiphtheriticum in 1 case. The clinical efficacy was good in all 9 cases, the efficacy rate was 100%. All the bacteria were eliminated. Side effects were not observed. From these results, it appears that FMOX is a valuable drug in the treatment of respiratory tract infections.
 ...
PMID:[Clinical evaluations of flomoxef in respiratory tract infections]. 344 19

Thirty-five patients suffering from soft tissue infections (12), upper UTIs (6), bronchopneumonia (6), septicaemia (2), chronic osteomyelitis (2), intra-abdominal abscess (2), liver abscess (1), lung abscess (1), acute cholangitis (1), thoracic empyema (1) and chronic prostatitis (1) were given imipenem/cilastatin for 6-21 days. In 22 patients several aggravating factors coexisted, while infection in 16 patients was polymicrobial. The following pathogens were implicated: Pseudomonas aeruginosa (21), Escherichia coli (15), Enterobacter cloacae (6), Proteus spp. (3), Klebsiella pneumoniae(3), Citrobacter freundii (1), Salmonella enteritidis (1), Acinetobacter spp. (4), Haemophilus influenzae (2), Bacteroides fragilis (1) and Peptococcus saccharolyticus (1) with MICs to imipenem ranging between 0.5 and 8 mg/l. A successful clinical response was observed in 91.4% of the patients, while pathogens were eradicated in 75.9%, persisted in 24.2% and recurred, in 9.1% of patients, with development of resistance to imipenem in two Ps. aeruginosa strains. Against 150 multiresistant strains of Ps. aeruginosa, 40% of which were resistant to amikacin, 86.4% and 88.9% were found sensitive to ceftazidime and imipenem respectively. It is concluded that imipenem provides the possibility of treating successfully multiresistant and polymicrobial infections with a single antimicrobial.
 ...
PMID:Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens. 346 91

66 patients were given daily doses of ofloxacin between 400 and 800 mg for 10 days to 6 months. They were suffering from exacerbation of chronic bronchitis (15), soft tissue phlegmon (11), complicated urinary tract infections (7), bronchopneumonia (7), chronic osteomyelitis in exacerbation (8), chronic prostatitis in exacerbation (5), lower urinary tract infections (3), chronic otitis media (3), acute otitis (3), acute bronchitis (1), lung abscess (2) or liver abscess (1). Pathogens included Pseudomonas aeruginosa (24), Haemophilus influenzae (16), Proteus mirabilis (6), Escherichia coli (6), Enterobacter cloacae (6), Providencia stuartii (2), Serratia marcescens (2), Citrobacter diversus (1), Salmonella enteritidis (1), Acinetobacter anitratus (1), Staphylococcus aureus (1) and Streptococcus pneumoniae (1). In 35 patients (53%), several aggravating factors coexisted. MICs of ofloxacin ranged from less than or equal to 0.06 to 2 mg/L. Clinically, 65% of the patients were considered as cured, 17% improved and 18% failed to respond. Bacteriologically, pathogens were eradicated in 62%, persisted in 16% and relapsed in 22%. Adverse reactions included gastrointestinal disturbances (4), rash plus facial oedema (1), abnormal liver function (2) and leucopenia (1).
 ...
PMID:Efficacy and tolerance of oral ofloxacin in treating various infections. 348 12

Comparisons were made in the mortality associated with an inhaled dose of viable Haemophilus pleuropneumoniae type 5, strain J45, between adult C3H/HeN and C3H/HeJ mice. Mice of both strains were also challenged with Escherichia coli strains O111:B4 and J5. The 50% lethal dose (LD50) of H. pleuropneumoniae in C3H/HeN mice was calculated to be 10(6.5) CFU. At a mean dose of 10(6.7) CFU a 46% mortality rate occurred in C3H/HeN mice, whereas only 10% of the C3H/HeJ mice died (P less than 0.01). Deaths occurred significantly earlier in C3H/HeN mice (P less than 0.01). No deaths occurred later than 12 h postinfection in either group. Pulmonary lesions in the mice that died were similar to those in pigs that die during the acute phase of H. pleuropneumoniae infection. In surviving mice of both strains, a mild resolving interstitial and bronchopneumonia was present which was not typical of subacute H. pleuropneumoniae infections in swine. Quantitative bacterial isolations from the lungs, liver, and spleen indicate that H. pleuropneumoniae did not multiply in the lungs, was rapidly cleared, and did not become systemic. No deaths occurred in the mice inoculated with E. coli J5 or O111:B4 at mean doses of 10(6.3), 10(7.2), and 10(8.5) CFU, and 10(6.4), 10(7.5), and 10(8.2) CFU, respectively. The difference in the mortality rate between the C3H/HeN and C3H/HeJ mice suggests that endotoxin may be involved in acute deaths in pigs infected with H. pleuropneumonia. As indicated by the E. coli challenge, however, other factors are also likely to be involved. Because of the differences in the pathology and microbiology following H. pleuropneumoniae pulmonary infections in mice and pigs, mice do not appear to be an accurate model of the overall disease in swine.
 ...
PMID:Resistance of C3H/HeJ mice to the effects of Haemophilus pleuropneumoniae. 352 83

Purulent bronchopneumonia was induced in 12 young calves inoculated endotracheally with a total of 2 to 8 X 10(10) viable Haemophilus somnus organisms. Calves treated before inoculation of bacteria with dexamethasone had more extensive lung changes than nontreated calves. Two of six dexamethasone-pretreated calves died while none of the non-pretreated calves died in the 12-day experimental period. Cranial-ventral gray to red lung consolidations with multifocal abscesses were present in all calves. Histologic examination revealed purulent to fibrinopurulent bronchiolitis accompanied by alveolar filling with fibrin, neutrophils, and macrophages. In addition, peribronchiolar fibrosis and bronchiolitis obliterans were common as were interlobular fibrosis and thrombosis of interlobular and pleural lymphatics. Focal to diffuse ulceration of bronchiolar epithelium was present in five of 12 lungs. Abscessation and severe alveolar filling with fibrin, red blood cells, and streaming inflammatory cells were present in dexamethasone-treated calves. H. somnus was isolated from lungs of all 12 calves. Complement fixation and microagglutination antibody titers to H. somnus antigens increased in most calves following infection with H. somnus. This model of H. somnus pneumonia closely resembles the naturally occurring disease.
 ...
PMID:Experimental Haemophilus somnus pneumonia in calves. 357 7

Sixty-one of 68 sets of bovine lungs from which only Haemophilus somnus was isolated had microscopic lesions of purulent bronchiolitis and bronchopneumonia. In 37 of 61 lungs, the bronchiolar exudates were markedly necrotic with accompanying necrosis of the adjacent bronchiolar epithelium. Bronchiolitis obliterans was prominent in 23 of 28 lungs affected with chronic lesions with abscesses present in seven. Alveolar filling with inflammatory cells (neutrophils with fewer macrophages) was limited to peribronchiolar alveoli in 25 of 61 lungs and was multifocal to diffuse in the other 36. Lesions in the remaining lungs (7 of 68) were classified as fibrinous pneumonia with bronchiolitis (2), fibrinous pleuritis (2), suppurative interstitial pneumonia with vasculitis (2), and diffuse congestion (1).
 ...
PMID:Microscopic lesions associated with the isolation of Haemophilus somnus from pneumonic bovine lungs. 398 57

Sulbactam/cefoperazone (SBT/CPZ) was used in pediatric patients with acute infections, and the following results were obtained. SBT/CPZ was administered to 18 pediatric patients with acute infections. Out of them, 14 patients, i.e., 3 with acute tonsillitis, 1 with acute laryngitis, 1 with acute bronchitis, 4 with acute pneumonia, 4 with bronchopneumonia, 1 with pyothorax, were adopted for the evaluation, and the other 4 were excluded because they were judged inadequate for clinical efficacy evaluation. The clinical efficacy of SBT/CPZ was assessed as excellent in 4, good in 9 and fair in 1. The effective rate was 92.9%. In 6 cases causative organisms were detected, i.e., Haemophilus influenzae in 3, Klebsiella in 1 and Staphylococcus aureus in 2 cases. Eradication of these organisms was confirmed in all cases except for 1 patient with pyothorax caused by S. aureus. The doses used in 12 out of the evaluated 14 cases ranged from 58.4 to 80 mg/kg/day, 84.1 mg/kg/day was used in 1 case and 101.4 mg/kg/day was used in 1 case with pyothorax. Patients with severe infections were generally given large doses. The frequency of administration was 3 times per day except 1 case, and intravenous drip infusion was used in all cases. The duration of treatment was 2- less than 3 days for 7 cases, 3-5 days for 6 cases and 9 days for 1 case (pyothorax). No clinical side effects were observed in any case. In laboratory examinations, a slight elevation of GOT was observed in 1 case, but no abnormal findings in the other cases. From the above results, SBT/CPZ was considered to be a highly useful drug in the treatment of pediatric infections.
 ...
PMID:[Clinical study on sulbactam/cefoperazone in the field of pediatrics]. 609 60

Cefaclor and tetracycline were compared in a single-blind study designed to treat patients with acute bacterial bronchitis and acute exacerbations of chronic bronchitis. Twenty-five pathogens (including 19 of Haemophilus influenzae and four of Streptococcus pneumoniae) were obtained from sputum samples of 48 patients. No pathogen could be cultured from the sputum of 23 patients. All of these pathogens were susceptible to cefaclor, while 12 (63%) of the 19 H influenzae isolates and three of the four S pneumoniae isolates were resistant to tetracycline. When the susceptibility of the 25 isolates to other commonly used antibacterials was tested, 18 isolates of H influenzae were resistant to erythromycin and one was resistant to ampicillin. (One H influenzae isolate was not tested for erythromycin susceptibility.) The four isolates of S pneumoniae were susceptible to erythromycin and ampicillin. Satisfactory results were achieved in 21 of the 23 patients receiving cefaclor. After four to six days of cefaclor therapy, the other two patients were diagnosed as having bronchopneumonia, and parenteral antibiotic therapy was instituted. Of the 25 patients assigned to the tetracycline regimen, three with resistant H influenzae had unsatisfactory clinical responses and required parenteral antibiotic therapy for recovery. Although patients were randomly assigned to therapy, only three of the 16 patients infected with tetracycline-resistant organisms were assigned to the tetracycline group, and all three failed to respond to treatment. Had the patients been more evenly distributed according to susceptibilities, it is possible that more treatment failures would have occurred in the group receiving tetracycline.
 ...
PMID:A comparison of cefaclor and tetracycline in the treatment of bacterial bronchitis. 623 Nov 4

To evaluate the antibacterial potency of cefotiam (CTM) clinical and laboratory studies were carried out and the results were as follows. Clinical evaluation and adverse reaction CTM was given to total of 23 patients, 10 with bronchopneumonia, 10 with bronchitis and one each with cystitis, enteritis and suspected sepsis. Overall efficacy rate was 78.3% (18/23) (excellent 9, good 9, fair 3, poor 2). Only 1 case showed a side effect of slightly elevated GOT and GPT. Antibacterial activities MIC of CTM against isolates from sputum was investigated on those patients mentioned above and was compared with MIC of CEZ and CMZ. CTM showed superior antibacterial activity against almost all strains. Especially on Haemophilus and Klebsiella antibacterial activity of CTM was impressive. Organisms in sputum Four out of 8 causative bacteria disappeared and 1 out of 8 decreased after administration of CTM. Thus CTM is considered to be the useful drug for the treatment of respiratory infection.
 ...
PMID:[Antibacterial potency of cefotiam based on the clinical effect, MIC and decrement of organisms in the sputum]. 631 12


<< Previous 1 2 3 4 5 6 7 Next >>